BCIQ Profiles

Company Profile Report
0607 Adu price
BioCentury & Getty Images

Product Development

Biogen unswayed by ICER assessment in aducanumab pricing

Jun 8, 2021 | 1:47 AM GMT

Biogen’s list price for aducanumab would only be cost-effective for a drug that completely halted dementia progression, according to ICER, adding controversy to the already contentious debate over whether

Read the full 501 word article

How to gain access

Continue reading with a
two-week free trial.